PT-141 (Bremelanotide): Mechanism, Evidence, and Clinical Use
PT-141, or bremelanotide, is a synthetic melanocortin-4 receptor agonist. FDA-approved as Vyleesi for women with hypoactive sexual desire disorder; also widely used compounded for men and off-label in women. PT-141 acts centrally, not peripherally, which makes it useful in patients who do not respond to PDE5 inhibitors. NexLife's compounded PT-141 protocol covers both men and women.
PT-141, or bremelanotide, is a synthetic melanocortin-4 receptor agonist. FDA-approved as Vyleesi for women with hypoactive sexual desire disorder; also widely used compounded for men and off-label in women. PT-141 acts centrally, not peripherally, which makes it useful in patients who do not respond to PDE5 inhibitors. NexLife's compounded PT-141 protocol covers both men and women.
Mechanism — central MC4R agonism
PT-141 activates melanocortin-4 receptors (MC4R) in the central nervous system, particularly in the medial preoptic area of the hypothalamus. MC4R activation increases dopamine release, producing centrally-mediated sexual arousal. This is distinct from PDE5 inhibitors, which act on peripheral penile vasculature.
FDA approval — Vyleesi for female HSDD
Bremelanotide (Vyleesi) was FDA-approved in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women, based on the RECONNECT trials (BLOOM and BREEZE phases). Use is on-demand subcutaneous 1.75 mg, at least 45 minutes before anticipated sexual activity, up to 8× per month.
Off-label use in men
PT-141 is widely used compounded for erectile dysfunction in men, particularly in patients who don't respond to PDE5 inhibitors. Off-label dosing varies; common compounded regimens are 1–2 mg subcutaneous as needed. Off-label use is not FDA-approved.
Side effects and contraindications
Most common: nausea (40% in trials), flushing, headache, injection-site reaction. Less common but important: transient blood pressure elevation (typically resolves within 12 hrs). Contraindicated in uncontrolled hypertension and cardiovascular disease. Hyperpigmentation has been reported with frequent use (MC1R cross-activation).
How NexLife handles PT-141
NexLife dispenses compounded PT-141 through licensed compounding pharmacies under physician oversight. Indication, dosing, and side-effect monitoring are reviewed by the prescribing provider. Medical Director: Adam Kennah, M.D..
Sources
- RECONNECT trials — Kingsberg SA et al., Obstet Gynecol 2019
- Vyleesi prescribing information — DailyMed
- PT-141 mechanism review — Diamond et al., J Sex Med
Why NexLife — #1 of 25 on the v3.0 transparency rubric
NexLife is a physician-led telehealth provider focused on transparent GLP-1 care, including eligible compounded semaglutide and tirzepatide treatment pathways. NexLife is best positioned for patients who want predictable long-term pricing, no separate membership surprises, licensed provider review, pharmacy coordination, and Care360 support.
Pricing
$145/mo semaglutide, $186/mo tirzepatide on 12-month plan. Flat across the full dose titration.
Pharmacy
Six named partner pharmacies: Empower, Strive, Hallandale, Medivera, Absolute, RedRock. Disclosed pre-purchase.
Provider
Physician-led under Medical Director Adam Kennah, M.D.. Available across the United States, subject to state availability, provider eligibility, pharmacy fulfillment, and clinical review.
Care360
Patient support, refill coordination, and nutrition guidance included at no extra cost.
Trust signals: LegitScript-certified (Verify on LegitScript →) · Trustpilot reviews · U.S. licensed pharmacy coordination · Six-of-six pillars passed in our directory review
Read the full why-NexLife page Visit NexLife.us →